Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial therapy for patients with chronic lymphocytic leukemia.

William G Wierda1, Susan M O'Brien

  • 1Department of Leukemia, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. wwierda@mdanderson.org

Seminars in Oncology
|April 18, 2006
PubMed
Summary

Frontline treatments for chronic lymphocytic leukemia (CLL) now aim for complete remission and minimal residual disease. New combination therapies, including monoclonal antibodies, are improving remission duration and survival outcomes for CLL patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

American journal of hematology·2026
Same author

Unfinished business in chronic lymphocytic leukemia: translational and clinical priorities for a cure.

Blood·2026
Same author

Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Developing MRD as an early endpoint for accelerated approval in CLL.

Seminars in hematology·2026
Same author

Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.

Blood advances·2026

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Chronic lymphocytic leukemia (CLL) treatment has evolved significantly.
  • The primary goals are increasing complete remission (CR) rates and eradicating leukemia cells.
  • New therapeutic strategies are crucial for improving patient outcomes.

Purpose of the Study:

  • To review recent advancements in frontline therapies for chronic lymphocytic leukemia (CLL).
  • To discuss the role of novel agents and combination regimens.
  • To explore the significance of minimal residual disease assessment.

Main Methods:

  • Review of recent clinical studies and literature on CLL frontline treatment.
  • Analysis of combination regimens incorporating monoclonal antibodies.

Related Experiment Videos

  • Evaluation of diagnostic techniques for minimal residual disease detection.

    • Main Results:

    • Effective combination regimens, including monoclonal antibodies, have been developed.
    • Minimal residual disease assessment may offer insights into therapy effectiveness.
    • New prognostic factors have been identified, but their predictive utility for response is under investigation.

    Conclusions:

    • Significant progress has been made in developing effective CLL frontline therapies.
    • Current treatments are improving remission duration, aiming to enhance overall survival.
    • Further research is needed to establish the role of prognostic factors in predicting treatment response.